Quantitative analysis of brain atrophy in patients with xeroderma pigmentosum group A carrying the founder mutation in Japan
- PMID: 28991657
- DOI: 10.1016/j.jns.2017.08.3238
Quantitative analysis of brain atrophy in patients with xeroderma pigmentosum group A carrying the founder mutation in Japan
Abstract
Introduction: Xeroderma pigmentosum (XP) is an inherited congenital disease presenting with dermatological and neurological manifestations. In Japan, XP complementation group A (XP-A) is most frequently observed in eight clinical subtypes, and the homozygous founder mutation, IVS3-1G>C in XPA, suffer from severe manifestations including progressive brain atrophy since childhood. In this study, we used magnetic resonance imaging (MRI) and applied volumetric analysis to elucidate the start and the progression of the brain atrophy in these patients.
Material and methods: Twelve Japanese patients with XP-A carrying the founder mutation and seven controls were included. MRI was performed for each patient once or more. Three-dimensional T1 weighted images were segmented to gray matter, white matter, and cerebrospinal fluid, and each volume was calculated.
Results: Conventional MRI demonstrated progressive whole brain atrophy in patients with XP-A. Moreover, volumetric analysis showed that reductions of total gray matter volumes (GMV) and total brain volumes (TBV) started at the age of five. The slope of reduction was similar in all cases. The GMV and TBV values in controls were higher than those in XP-A cases after the age of five.
Conclusions: This is the first quantitative report presenting with the progression of brain atrophy in patients with XP-A. It is revealed that the brain atrophy started from early childhood in Japanese patients with XP-A carrying the homozygous founder mutation.
Keywords: Brain atrophy; Founder mutation; Gray matter volume; XP-A; Xeroderma pigmentosum.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
A prevalent mutation with founder effect in xeroderma pigmentosum group C from north Africa.J Invest Dermatol. 2010 Jun;130(6):1537-42. doi: 10.1038/jid.2009.409. Epub 2010 Jan 7. J Invest Dermatol. 2010. PMID: 20054342
-
Clinical and genetic characteristics of xeroderma pigmentosum in Nepal.J Eur Acad Dermatol Venereol. 2018 May;32(5):832-839. doi: 10.1111/jdv.14717. Epub 2017 Dec 18. J Eur Acad Dermatol Venereol. 2018. PMID: 29178624
-
Mutational spectrum of Xeroderma pigmentosum group A in Egyptian patients.Gene. 2014 Jan 1;533(1):52-6. doi: 10.1016/j.gene.2013.09.125. Epub 2013 Oct 14. Gene. 2014. PMID: 24135642
-
Xeroderma pigmentosum complementation group F: Report of a case and review of Japanese patients.J Dermatol. 2015 Sep;42(9):897-9. doi: 10.1111/1346-8138.12942. Epub 2015 May 25. J Dermatol. 2015. PMID: 26010807 Review.
-
[Neurological manifestations and molecular basis of group A xeroderma pigmentosum].Nihon Rinsho. 1993 Sep;51(9):2488-93. Nihon Rinsho. 1993. PMID: 8105118 Review. Japanese.
Cited by
-
Differences in peripheral neuropathy in xeroderma pigmentosum complementation groups A and D as evaluated by nerve conduction studies.BMC Neurol. 2021 Oct 9;21(1):393. doi: 10.1186/s12883-021-02414-2. BMC Neurol. 2021. PMID: 34627174 Free PMC article.
-
Peripheral neuropathies associated with DNA repair disorders.Muscle Nerve. 2023 Feb;67(2):101-110. doi: 10.1002/mus.27721. Epub 2022 Oct 3. Muscle Nerve. 2023. PMID: 36190439 Free PMC article. Review.
-
Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression.Brain. 2023 Dec 1;146(12):5044-5059. doi: 10.1093/brain/awad266. Brain. 2023. PMID: 38040034 Free PMC article.
-
Cell migration is impaired in XPA-deficient cells.FASEB Bioadv. 2022 Dec 12;5(2):53-61. doi: 10.1096/fba.2022-00084. eCollection 2023 Feb. FASEB Bioadv. 2022. PMID: 36816512 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources